Profit Pressure Deepens—Watch for CPG Turnaround Progress
EID Parry faces a second consecutive quarter of earnings weakness as the street revises FY27 guidance down. The watch: whether the Nutraceuticals push and CPG breakeven path can offset commodity-linked margin compression.
What to Expect
For Q2 FY27, watch three things: consolidated revenue (expect ~₹8,900–9,100 Cr on a comparable run-rate, anchored to Q1's ₹9,018 Cr and flat-to-modest seasonal headwinds in the sugar half-year), EBITDA margins (likely compressed vs. prior year as commodity cost pass-through lags in the packaged goods business, even as Nutraceuticals improves), and PAT (expect ₹100–140 Cr, with downside risk given Q1's 42% YoY decline to ₹142 Cr). A strong print would show revenue in line or better, with EBITDA margin stabilization above 8.5% and PAT holding near ₹140 Cr. A weak print would see revenue flat YoY or down, margins compress further, and PAT fall toward ₹100 Cr or below.
~₹8,900–9,100 Cr
Q1 was ₹9,018 Cr; expect modest seasonal flattish, ~+1% YoY at midpoint
~8–9%
Q1 was 8.7% (EBITDA ₹781 Cr); watch for commodity headwind offset by CPG/Nutra mix
~₹100–140 Cr
Q1 fell 42% YoY to ₹142 Cr (profit base lower); street now models continued pressure
Revenue –4.5%, EPS –4.9%
Street recently revised FY27 guidance lower; full-year weakness baked in
On Track?
EID Parry is tracking below the Street's (now-lower) expectations for FY27 profitability. Q1 FY27 was a wake-up call: revenue grew 3.4% YoY but PAT collapsed 42% as margin compression hit harder than expected. The analyst consensus has responded by cutting FY27 targets 17% (target price revised from ₹1,409 to ₹1,166), signaling a near-term earnings trough and a wait-and-see on the CPG turnaround. The company's stated expectation that the packaged goods division would reach quarterly breakeven within 4–5 quarters (a guide issued earlier in FY27) is now a critical credibility test. If Q2 shows continued PAT pressure without a clear path to margin recovery, the Street will push guidance further lower.
What the Street Says
Since Last Quarter
A quiet quarter operationally, with two noteworthy moves:
Oct 16, 2026
ESG Rating: 63 (Adequate) – NSE Ratings
Routine disclosure; no operational impact
Oct 9–12, 2026
CIO resignation + CTO appointment
Organizational refresh; no strategy signal
Sep 22, 2026
Trading window closure (Oct 1–Q2 result)
Standard pre-results blackout; watch for post-result insider activity
Aug 10, 2026
Block deal: SBI MF buys 22.15L shares @ ₹795; SAGEONE sells 22.15L @ ₹795
Large institutional repositioning near Q1 results; no price surprise
Aug–Oct 2026
FII ownership down 1pp QoQ to 11.21% (from 12.21%)
Marginal foreign fund outflow; retail ownership steady
No major red flags: the RTA address change (Nov 3) is administrative. Ownership is stable apart from the expected FII drift on weak earnings. The focus remains squarely on execution—whether CPG margins and Nutra growth can turn the narrative.
What to Watch on Result Day
1 · Consolidated EBITDA Margin
If it holds above 8.5%, the Street breathes. Below 8%, expect downgrades to FY27 consensus. Watch the breakdown: CPG margin (the locus of pressure) and Nutra margin (the growth story). Nutra hitting 12–15% is do-or-die for the investment case.
2 · CPG Division Progress Toward Breakeven
Management flagged 4–5 quarter path to quarterly breakeven. Q2 should show a tightening loss or flat operating performance. If the loss widens, the credibility of that timeline evaporates. Any management commentary on cost reduction or pricing power will anchor the Street's reset on turnaround timing.
3 · FY27 Full-Year Guidance Hold or Revision
The Street is now modeling –4.5% revenue and –4.9% EPS for FY27 on a (just-reset) lower base. If management cuts guidance again, expect a re-rating down. Any affirmation or modest upside surprise on FY27 guidance, backed by CPG visibility, could stabilize the stock near ₹1,166 target.
EID Parry faces a critical inflection: a commodity-linked margin squeeze in Q2 (and beyond), a CPG division mid-turnaround, and a Street that has just marked down the whole year. The stock is down 48% from its high (₹1,247), and the 17% target-price cut signals the Street's loss of confidence in near-term recovery. What matters on Nov 13: whether the Nutraceuticals division can deliver on its 12–15% margin promise, whether CPG losses narrow materially on the path to breakeven, and whether management reaffirms (or revises further) FY27 guidance. Expect muted trading post-result unless there's a management surprise on Nutra growth or CPG recovery timing.
Informational and educational content only. Not investment advice.